Vaccines and Antibodies

This platform brings together Australia’s experience and expertise to facilitate the conduct of Phase I and Phase II clinical trials of SARS-CoV-2 vaccine candidates. Led by the Doherty Institute in partnership with experienced Victorian and Australian clinical trials groups, it will facilitate a coordinated response that will enable Australia’s presence in the global raft of clinical trials of SARS-CoV-2 vaccine candidates and prophylactic monoclonal antibodies. Research participation will also provide improved access to vaccines for use in Australia once efficacy and safety is established and vaccines are licensed.